CN1665531A - 甲基化的免疫刺激性寡核苷酸和利用这些寡核苷酸的方法 - Google Patents

甲基化的免疫刺激性寡核苷酸和利用这些寡核苷酸的方法 Download PDF

Info

Publication number
CN1665531A
CN1665531A CN038162296A CN03816229A CN1665531A CN 1665531 A CN1665531 A CN 1665531A CN 038162296 A CN038162296 A CN 038162296A CN 03816229 A CN03816229 A CN 03816229A CN 1665531 A CN1665531 A CN 1665531A
Authority
CN
China
Prior art keywords
methylated
lipid
nucleic acid
antigen
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN038162296A
Other languages
English (en)
Chinese (zh)
Inventor
英·K·塔姆
肖恩·森普尔
桑德拉·克利穆克
加尼亚·奇克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inex Pharmaceuticals Corp
Original Assignee
Inex Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/290,545 external-priority patent/US20030125292A1/en
Application filed by Inex Pharmaceuticals Corp filed Critical Inex Pharmaceuticals Corp
Publication of CN1665531A publication Critical patent/CN1665531A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN038162296A 2002-05-10 2003-05-12 甲基化的免疫刺激性寡核苷酸和利用这些寡核苷酸的方法 Pending CN1665531A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US37934302P 2002-05-10 2002-05-10
US60/379,343 2002-05-10
US10/290,545 US20030125292A1 (en) 2001-11-07 2002-11-07 Mucoscal vaccine and methods for using the same
US10/290,545 2002-11-07
US46064603P 2003-04-04 2003-04-04
US60/460,646 2003-04-04

Publications (1)

Publication Number Publication Date
CN1665531A true CN1665531A (zh) 2005-09-07

Family

ID=29424457

Family Applications (1)

Application Number Title Priority Date Filing Date
CN038162296A Pending CN1665531A (zh) 2002-05-10 2003-05-12 甲基化的免疫刺激性寡核苷酸和利用这些寡核苷酸的方法

Country Status (10)

Country Link
EP (2) EP1503793A2 (enExample)
JP (2) JP2005532315A (enExample)
CN (1) CN1665531A (enExample)
AT (1) ATE411815T1 (enExample)
AU (2) AU2003229434A1 (enExample)
CA (2) CA2484266A1 (enExample)
DE (1) DE60324270D1 (enExample)
IL (1) IL165107A0 (enExample)
MX (1) MXPA04011127A (enExample)
WO (2) WO2003094963A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109985234A (zh) * 2019-04-12 2019-07-09 南华大学 一种梅毒螺旋体dna疫苗及其应用
CN116602920A (zh) * 2023-04-18 2023-08-18 中国科学技术大学 一种透皮肽修饰、含有Ce6和CpG的脂质体及应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE69932717T2 (de) 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa Methoden und produkte zur induzierung mukosaler immunität
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
DK2241325T3 (da) 2002-10-29 2012-04-10 Coley Pharm Group Inc Anvendelse af CPG-oligonukleotider til behandling af Hepatitis Cvirusinfektion
CA2536139A1 (en) 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
WO2010062697A2 (en) 2008-10-30 2010-06-03 Peixuan Guo Membrane-integrated viral dna-packaging motor protein connector biosensor for dna sequencing and other uses
CN102574927B (zh) 2009-09-28 2015-01-07 希森美康株式会社 产生抗甲基化dna抗体的杂交瘤及其利用
AU2021307553A1 (en) * 2020-07-14 2023-02-16 Evaxion Biotech A/S APC targeting units for immunotherapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0772619T4 (da) * 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
FI107974B (fi) * 1999-07-14 2001-10-31 Nokia Networks Oy Menetelmä ja järjestelmä tilastointiin puhelinkeskusjärjestelmässä
WO2001015726A2 (en) * 1999-08-27 2001-03-08 Inex Pharmaceuticals Corp. Compositions for stimulating cytokine secretion and inducing an immune response
US20030119774A1 (en) * 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
US20030125292A1 (en) * 2001-11-07 2003-07-03 Sean Semple Mucoscal vaccine and methods for using the same

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109985234A (zh) * 2019-04-12 2019-07-09 南华大学 一种梅毒螺旋体dna疫苗及其应用
CN116602920A (zh) * 2023-04-18 2023-08-18 中国科学技术大学 一种透皮肽修饰、含有Ce6和CpG的脂质体及应用
CN116602920B (zh) * 2023-04-18 2024-03-19 中国科学技术大学 一种透皮肽修饰、含有Ce6和CpG的脂质体及应用

Also Published As

Publication number Publication date
EP1503793A2 (en) 2005-02-09
CA2485400A1 (en) 2003-11-20
DE60324270D1 (de) 2008-12-04
JP2005532315A (ja) 2005-10-27
WO2003094963A2 (en) 2003-11-20
EP1506010B1 (en) 2008-10-22
WO2003094828A2 (en) 2003-11-20
WO2003094963A3 (en) 2004-02-12
WO2003094828A3 (en) 2004-02-05
AU2003229434A1 (en) 2003-11-11
AU2003229434A8 (en) 2003-11-11
IL165107A0 (en) 2005-12-18
CA2484266A1 (en) 2003-11-20
ATE411815T1 (de) 2008-11-15
AU2003229433A1 (en) 2003-11-11
JP2005530761A (ja) 2005-10-13
MXPA04011127A (es) 2005-07-01
EP1506010A2 (en) 2005-02-16
AU2003229433B2 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
US20040009943A1 (en) Pathogen vaccines and methods for using the same
CN1665531A (zh) 甲基化的免疫刺激性寡核苷酸和利用这些寡核苷酸的方法
US8420615B2 (en) Immunostimulatory oligonucleotide multimers
US20050191342A1 (en) Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
JP5721441B2 (ja) 免疫賦活剤／アジュバントとしての式（Ｉ）（ＮｕＧｌＸｍＧｎＮｖ）ａで表される核酸分子及びその誘導体
CN102517292B (zh) 免疫刺激性寡核糖核苷酸
CN1501811A (zh) 用于刺激细胞因子分泌和诱导免疫应答的组合物
US20030125292A1 (en) Mucoscal vaccine and methods for using the same
JP2005526497A (ja) 免疫刺激性、共有結合性脂質化オリゴヌクレオチド
AU2002340662A1 (en) Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
US20040009944A1 (en) Methylated immunostimulatory oligonucleotides and methods of using the same
US20040013649A1 (en) Cancer vaccines and methods of using the same
WO2018067822A1 (en) Methods to alter the tumor microenvironment for effective cancer immunotherapy
KR20210003695A (ko) 신규 핵산과 항원 결정기를 포함하는 나노 복합체를 기반으로 하는 범용 백신 플랫폼
EP1505942B1 (en) Pathogen vaccines and methods for using the same
WO2022034555A1 (en) Polynucleotide constructs and uses thereof
US20200376101A1 (en) Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Deliver System
WO2025240477A1 (en) Methods and materials for enhancing delivery of nucleic acid to cells
CN1852917A (zh) 使用免疫刺激性寡核苷酸和/或免疫子化合物结合细胞因子和/或化疗剂或放射治疗对免疫系统的协同刺激作用
JP2023088977A (ja) 樹状細胞療法においてｅｘ ｖｉｖｏでの抗原のプロセシングと提示を亢進させるための合成ベクターとしての脂質
CN101331229A (zh) 免疫刺激性寡核糖核苷酸
CN1835963A (zh) 稳定的免疫调节寡核苷酸

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20050907